Unnatiben S Patel

Dr. Unnatiben S Patel

Avanti Polar Lipids (United States), Alabaster, Alabama, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
HJH. Surangi N. Jayawardena
H. Surangi N. Jayawardena
SLSajani H. Liyanage
Sajani H. Liyanage
KRKavini Rathnayake
Kavini Rathnayake
UPUnnatiben S Patel
Unnatiben S Patel
Mingdi YanMingdi Yan
Mingdi Yan

13 July 2021 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
KPKrunal Y. Patel
Krunal Y. Patel
ZDZarna R. Dedania
Zarna R. Dedania
RDRonak R. Dedania
Ronak R. Dedania
UPUnnatiben S Patel
Unnatiben S Patel
Background: Quality by design (QbD) refers to the achievement of certain predictable quality with desired and predetermined specifications. A quality-by-design approach to method development can potentially lead to a more robust/rugged method due to emphasis on risk assessment and management than traditional or conventional approach. An important component of the QbD is the understanding of dependent variables, various factors, and their interaction effects by a desired set of experiments on the responses to be analyzed. The present study describes the risk based HPLC method development and validation of ceftriaxone sodium in pharmaceutical dosage form. Results: An efficient experimental design based on central composite design of two key components of the RP-HPLC method (mobile phase and pH) is presented. The chromatographic conditions were optimized with the Design Expert software 11.0 version, i.e., Phenomenex ODS column C18 (250 mm × 4.6 mm, 5.0 μ), mobile phase used acetonitrile to water (0.01% triethylamine with pH 6.5) (70:30, v/v), and the flow rate was 1 ml/min with retention time 4.15 min. The developed method was found to be linear with r2 = 0.991 for range of 10–200 μg/ml at 270 nm detection wavelength. The system suitability test parameters, tailing factor and theoretical plates, were found to be 1.49 and 5236. The % RSD for intraday and inter day precision was found to be 0.70–0.94 and 0.55–0.95 respectively. The robustness values were less than 2%. The assay was found to be 99.73 ± 0.61%. The results of chromatographic peak purity indicate the absence of any coeluting peaks with the ceftriaxone sodium peak. The method validation parameters were in the prescribed limit as per ICH guidelines. Conclusion: The central composite design experimental design describes the interrelationships of mobile phase and pH at three different level and responses to be observed were retention time, theoretical plates, and peak asymmetry with the help of the Design Expert 11.0 version. Here, a better understanding of the factors that influence chromatographic separation with greater confidence in the ability of the developed HPLC method to meet their intended purposes is done. The QbD approach to analytical method development was used for better understanding of method variables with different levels.

19 July 2020 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
KRKavini Rathnayake
Kavini Rathnayake
UPUnnatiben S Patel
Unnatiben S Patel
CPChi Pham
Chi Pham
AMAnna McAlpin
Anna McAlpin
TBTravis Budisalich
Travis Budisalich
SJSurangi N. Jayawardena
Surangi N. Jayawardena

21 April 2023 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
UPUnnatiben S Patel
Unnatiben S Patel
KRKavini Rathnayake
Kavini Rathnayake
NSNirupama Singh
Nirupama Singh
EHEmily C. Hunt
Emily C. Hunt

10 March 2021 in Nano Select
Verified
Journal Article
Open access
PDF file
UPUnnatiben S Patel
Unnatiben S Patel
KRKavini Rathnayake
Kavini Rathnayake
HJHemang Jani
Hemang Jani
KJKalana W. Jayawardana
Kalana W. Jayawardana
RDRijan Dhakal
Rijan Dhakal
SJSurangi N. Jayawardena
Surangi N. Jayawardena
To combat the rise of antibiotic resistant bacteria, it is essential to look upon other therapeutic solutions that do not solely depend upon conventional antibiotics. Here, we have designed a combinational therapeutic approach that kills bacteria with the conjunction of photothermal (PT) and antibiotic therapy. A near‐infrared (NIR) laser activated targeted drug delivery nano‐assembly delivers antibiotic as well as offer PT therapy (PTT). The synergistic application of both therapies increases the efficacy of treatment. The protected delivery of antibiotic and its release in the proximity of the bacteria surface reduces off‐target toxicity and reduce the efficacious dosage. Core of the nano‐assembly is composed of NIR active gold nanorods (GNRs) coated with a mesoporous silica nanoparticle (MSNP), which serves as a carrier for an anti‐tuberculosis drug bedaquiline (BDQ). The assembly was wrapped within a thermo‐sensitive liposome (TSL) conjugated to mycobacteria‐targeting peptide: NZX, GNR@MSNP@BDQ@TSL@NZX. NZX mediates adhesion of final nano‐assembly on mycobacteria surface. Upon NIR laser irradiation GNRs convert photo energy of the laser to localized heat, which melts TSL triggering release of BDQ. Antibacterial activity of final nano‐assembly against Mycobacterium smegmatis (Msmeg) was 20 folds more efficacious than the free drug equivalent. The final nano‐assembly could also successfully inhibit the growth of intracellular mycobacteria residing in lung cells.

12 September 2023 in ACS Omega
Verified
Journal Article
Open access
KRKavini Rathnayake
Kavini Rathnayake
UPUnnatiben S Patel
Unnatiben S Patel
EHEmily C. Hunt
Emily C. Hunt
NSNirupama Singh
Nirupama Singh
Nanoparticles have been suggested as drug-delivery systems for chemotherapeutic drugs to allow for controlled drug release profiles and selectivity to target cancer cells. In addition, nanoparticles can be used for the in situ generation and amplification of reactive oxygen species (ROS), which have been shown to be a promising strategy for cancer treatment. Thus, a targeted nanoscale drug-delivery platform could be used to synergistically improve cancer treatment by the action of chemotherapeutic drugs and ROS generation. Herein, we propose a promising chemotherapy strategy where the drug-loaded nanoparticles generate high doses of ROS together with the loaded ROS-generating chemotherapeutic drugs, which can damage the mitochondria and activate cell death, potentiating the therapeutic outcome in cancer therapy. In the present study, we have developed a dual-targeted drug-delivery nanoassembly consisting of a mesoporous silica core loaded with the chemotherapeutic, ROS-generating drug, paclitaxel (Px), and coated with a liposome layer for controlled drug release. Two different lung cancer-targeting ligands, folic acid and peptide GE11, were used to target the overexpressed nonsmall lung cancer receptors to create the final nanoassembly (MSN@Px) L-GF. Upon endocytosis by the cancer cells, the liposome layer was degraded by the intracellular lipases, and the drug was rapidly released at a rate of 65% within the first 20 h. In vitro studies confirmed that this nanoassembly was 8-fold more effective in cancer therapy compared to the free drug Px.